Fibrin Degradation Products (FDPs)

Excessive fibrinolysis results in accumulation of fibrin degradation products in the blood. When present in high concentration they may interfere with the coagulation pathway and platelet function. Increased levels are seen in secondary fibrinolysis associated with disseminated intravascular coagulation and in primary fibrinolysis (which may be associated with liver disease, prostatic carcinoma or thrombolytic therapy).

FDPs are elevated (usually > 40 ug/mL) in 85 to 100% of patients with acute DIC. Other causes of elevated FDPs include thromboembolism, myocardial infarction, surgery, and transplant rejection.  

Reference range was <5 ug/mL. 

This test was discontinued on November 1, 1999 and is considered obsolete.